Relay Therapeutics (RLAY) Q4 2025 Earnings

Yes. Relay Therapeutics reported Q4 2025 earnings of $-0.32 a share on Feb 26, 2026, beating the $-0.40 consensus estimate by 19.2%. Revenue was $7.0M against a $4.3M estimate.

Relay Therapeutics delivered a strong finish to fiscal 2025, beating Wall Street expectations on both the top and bottom lines as its pipeline progress and leaner cost structure took hold. The clinical-stage biotech posted a Q4 loss per share of $0.32, coming in 19.17% better than the consensus estimate of $0.40, while revenue of $7.00 million cleared the $4.34 million analyst forecast by 61.41%, driven largely by recognition of payments under its Exclusive License Agreement with Elevar Therapeutics. The net loss narrowed to $54.89 million from $76.00 million a year earlier, reflecting meaningful cuts to R&D and G&A spending following the company's 2024-2025 research restructuring. Shares surged roughly 19% to a 52-week high in the wake of the report, buoyed further by FDA Breakthrough Therapy designation for lead asset zovegalisib. With $554.52 million in cash and investments on hand, management projects a runway into 2029, and investors are watching closely for Phase 1/2 zovegalisib data at ESMO TAT in March 2026 as the next major catalyst.